PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.73%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-5.73%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-4.82%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-5.05%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-5.05%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3274.19%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-3274.19%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.86%
OCF/share CAGR of 47.86% while AVXL is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
47.86%
OCF/share CAGR of 47.86% while AVXL is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
47.86%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
60.77%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
60.77%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
60.77%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.11%
Negative asset growth while AVXL invests at 906.10%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.64%
We have a declining book value while AVXL shows 15.82%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.65%
Debt shrinking faster vs. AVXL's 25.86%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
6.08%
SG&A declining or stable vs. AVXL's 81.64%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.